Previous 10 | Next 10 |
Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug disc...
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, anno...
More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechn...
LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) Syndromes Phase 1b/2 for Advanced Soft Tissue Sarcoma Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme Phase 1b for Small Cell Lu...
WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs fo...
WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. PR Newswire JERSEY CITY, N.J. , March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional ...
East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certa...
Gainers: Morphic (MORF) +106%.Aemetis (AMTX) +58%.SOS (SOS) +43%.Canaan (CAN) +41%.electroCore (ECOR) +37%.Vector Acquisition (VACQU) +37%.The9 (NCTY) +36%.One Stop Systems (OSS) +30%.HCI Group (HCI) +29%.ZK International (ZKIN) +27%.Losers: Athenex (ATNX) -52%.O...
Gainers: Morphic (MORF) +104%, electroCore (ECOR) +51%, Apollo Endosurgery (APEN) +24%, ASLAN Pharmaceuticals (ASLN) +23%, Satsuma Pharmaceuticals (STSA) +19%.Losers: Athenex (ATNX) -51%, Ontrak (OTRK) -48%, CorMedix (...
Lixte Biotechnology (LIXT) enters agreement for purchase and sale of 1.3M shares of common stock, at a purchase price of $3.70 per share, in a registered direct offering; gross proceeds $4.19M. Closing expected on or about March 2, 2021.Gross proceeds from the offering are expected ...
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Company Name:
LIXT Stock Symbol:
OTCMKTS Market:
Lixte Biotechnology Holdings Inc. Website:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...